Nakano Toshiaki, Goto Shigeru, Lai Chia-Yun, Hsu Li-Wen, Ono Kazuhisa, Kawamoto Seiji, Lin Yu-Chun, Kao Ying-Hsien, Chiang Kuei-Chen, Ohmori Naoya, Goto Takeshi, Sato Shuji, Tu Chieh-Hsien, Jawan Bruno, Cheng Yu-Fan, Chen Chao-Long
Liver Transplantation Program and Department of Surgery, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Chang Gung University College of Medicine, 123 Ta-Pei Rd., Niao-Sung, Kaohsiung 833, Taiwan.
Transpl Immunol. 2007 Apr;17(3):147-52. doi: 10.1016/j.trim.2007.01.003. Epub 2007 Jan 24.
We recently reported that autoreactive antibody (Ab) against nuclear histone H1 had been identified as an immunosuppressive factor in a rat tolerogenic orthotopic liver transplantation (OLT) model. The present study aimed to determine whether the up-regulation of antihistone H1 Ab by histone H1 vaccination leads to tolerance.
Histone H1-immunized rats were established by intraperitoneal vaccination with histone H1 at every two-weekly interval. By using mixed lymphocyte reaction (MLR) and heterotopic heart transplantation (HHT), the alloreactive T cell response and allograft survival of histone H1-immunized rats were compared with those of control rats. Cytokine and cellular profiles in histone H1-immunized rats were determined by reverse transcriptase polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA) and flow cytometry.
Immunization with histone H1 in Freund's adjuvant induced alloreactive T cell unresponsiveness and prolonged heterotopic heart allograft survival. It also down-regulated the expression of major histocompatibility complex (MHC) class II and CD25 on splenic cells, elevated the T helper cell type 2 (Th2) skewing index (Interleukin (IL)-4/interferon (IFN)-gamma ratio or IL-4/IL-2 ratio) and modified the serum cytokine profiles.
The present results suggest that histone H1 vaccination of transplant recipients, which leads to the production of immunosuppressive factor and the modification of the cytokine/cellular profiles, has great potential as a tolerance therapy for prospective transplantation.
我们最近报道,在大鼠耐受性原位肝移植(OLT)模型中,已将针对核组蛋白H1的自身反应性抗体(Ab)鉴定为一种免疫抑制因子。本研究旨在确定通过组蛋白H1疫苗接种上调抗组蛋白H1抗体是否会导致免疫耐受。
通过每两周一次腹腔注射组蛋白H1建立组蛋白H1免疫大鼠。利用混合淋巴细胞反应(MLR)和异位心脏移植(HHT),将组蛋白H1免疫大鼠的同种异体反应性T细胞反应和同种异体移植物存活情况与对照大鼠进行比较。通过逆转录聚合酶链反应(RT-PCR)、酶联免疫吸附测定(ELISA)和流式细胞术测定组蛋白H1免疫大鼠的细胞因子和细胞谱。
用弗氏佐剂中的组蛋白H1免疫可诱导同种异体反应性T细胞无反应性,并延长异位心脏同种异体移植物的存活时间。它还下调了脾细胞上主要组织相容性复合体(MHC)II类和CD25的表达,提高了2型辅助性T细胞(Th2)偏向指数(白细胞介素(IL)-4/干扰素(IFN)-γ比值或IL-4/IL-2比值),并改变了血清细胞因子谱。
目前的结果表明,对移植受者进行组蛋白H1疫苗接种可导致免疫抑制因子的产生以及细胞因子/细胞谱的改变,作为一种前瞻性移植的免疫耐受疗法具有巨大潜力。